Product
Eureka
For R&D, Eureka makes reading and utilizing patents & technical documents easy.
Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
203 results about "Cell delivery" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Definition. A cell delivery vehicle is a matrix (made from natural or synthetic materials or a combination of the two) that can be combined with cells to be transplanted into a human or animal host.
Cell delivery system comprising a fibrous matrix and cells
Owner:THE RES FOUND OF STATE UNIV OF NEW YORK
Magnetically-controllable delivery system for therapeutic agents
InactiveUS20060041182A1Enhanced magnetizationReduce penetrationStentsElectrotherapyMagnetic gradientMagnetization
A magnetic delivery system for delivering a magnetizable particle to a location in a body, the device includes a magnetizable object implanted in the body, wherein the magnetizable object includes a plurality of segments distributed throughout the magnetizable object and wherein the segments are configured to provide a magnetic gradient for attracting the magnetizable particle and an external source of a magnetic field capable of (i) magnetizing the magnetizable particle and (ii) increasing a degree of magnetization of the magnetizable object and thereby creating the magnetic gradient. A drug delivery system including the magnetic delivery system and a magnetizable particle associated with a therapeutic agent and / or a cell. A cell delivery system based on the magnetic delivery system and a magnetizable particle associated with a cell. A method of using the magnetic delivery system for delivery of a therapeutic agent and / or a cell to a targeted location in a body.
Owner:DREXEL UNIV
Reversibly Masked Polymers
InactiveUS20080281041A1Reduce aggregationGenetic material ingredientsOther foreign material introduction processesLinkage conceptActive polymer
The present invention is directed to reversibly inactivation of membrane active polymers useful for cellular delivery of compounds. Described are polyconjugates systems that incorporate targeting, anti-opsonization, anti-aggregation, and transfection activities into small biocompatible in vivo delivery conjugates. The use of multiple reversible linkages connecting component parts provides for physiologically responsive activity modulation.
Owner:ARROWHEAD MADISON
Stem cells within gel microenvironments
This invention provides a system to embed stem cells within three-dimensional (3D) hydrogel microenvironments consisting of naturally derived proteins, proteoglycans and / or polysaccharides. Pure matrices or combinations of materials can be used. The method involves suspending stem cells in solutions of the matrix components of interest, emulsifying these solutions in a hydrophobic phase, triggering gelation of the matrix components by changing the environmental conditions, and collection of the resulting hydrogel beads. The unique bead format of this invention has the advantage of allowing the use of small amounts of rare matrix proteins. Bead preparations can be concentrated into a paste for use as a cell delivery vehicle to damaged tissues, either directly after encapsulation or after a period of culture to promote stem cell differentiation. Defined 3D microenvironments can guide stem cell differentiation, and the resulting beads can be used directly as a cell delivery vehicle in various tissue repair applications.
Owner:RENESSELAER POLYTECHNIC INST
Electromagnetic activation of gene expression and cell growth
InactiveUS20050059153A1Accelerating cell cycleReduce inflammationElectrotherapyMutant preparationAngiotensin receptorA-DNA
The invention is directed to a method for accelerating the cell cycle by delivering to a cell an effective amount of electromagnetic energy. The invention also provides a method for activating a cell cycle regulator by delivering to a cell an effective amount of electromagnetic energy. Also provided by the invention is a method for activating a signal transduction protein; a method for activating a transcription factor; a method for activating a DNA synthesis protein; and a method for activating a Receptor. A method for inhibiting an angiotensin receptor as well as a method for reducing inflammation also are provided by the present invention. The invention also is directed to a method for replacing damaged neuronal tissue as well as a method for stimulating growth of administered cells.
Owner:REGENESIS BIOMEDICAL
Vascular prosthesis having improved flexibility and nested cell delivery configuration
InactiveUS20060030934A1Increase flexibilityReduced delivery profileStentsBlood vesselsVascular prosthesisBiomedical engineering
Owner:NOVOSTENT CORP
Methods for producing block copolymer/amphiphilic particles
InactiveUS20060134221A1Enhance immune responsePowder deliveryAntiinfectivesLipid formationManufacturing cell
The invention relates to a method for manufacturing cell delivery particles, pharmaceutical component-particle dispersions, compositions comprising cell delivery particles and pharmaceutical compositions comprising pharmaceutical component-particle dispersions. The method comprises homogenization of mixtures comprising amphiphilic components and a block copolymer to form stable particles. The invention is also directed to cell delivery particles and pharmaceutical component-particle dispersions produced by the claimed methods and compositions comprising same. In certain embodiments, the cell delivery particles may further comprise co-lipids. The invention further relates to methods of generating an immune response, treating or preventing a disease or condition, or delivering a biologically active molecule to cells in vitro comprising administration of the pharmaceutical compositions described herein.
Owner:VICAL INC
Delivery system
Provided herein is a delivery system, including: (a) an optical sensor configured to detect data useful to create a map of a bodily surface; and (b) a printer operatively associated with the optical sensor and configured to deliver compositions (optionally including cells) to the bodily surface based upon the data or map. Methods of forming a tissue on a bodily surface of a patient in need thereof are also provided, as are methods, systems and computer program products useful for processing bodily surface data.
Owner:WAKE FOREST UNIV HEALTH SCI INC
Cell delivery catheters with distal tip high fidelity sensors
InactiveUS20090177183A1Accurately determinedReduce flow rateStentsBalloon catheterTransducerCatheter device
The present invention relates to over the wire cell delivery catheters with high fidelity sensors at their distal end. These catheters are comprised of flow rate sensors and / or pressure transducer sensors. These catheters can also be comprised of occlusion balloons. The catheters of the present invention allow for administration of the highest and safest dose of therapeutic agents, e.g., adipose derived regenerative cells, on an individualized basis.
Owner:LOREM VASCULAR PTE LTD
Remote detection of substance delivery to cells
InactiveUS20050112065A1Highly preventive effectIncreasing effect on proton relaxivityDiagnostics using lightDispersion deliveryLipid formationElectrochemical gradient
The present invention provides for the development of endocytosis-sensitive probes, and a remote method for measuring cellular endocytosis. These probes are based on the reduced water permeability of a nanoparticle or liposomal delivery system, and inherent degradability or disruption of barrier integrity upon endocytosis. The invention also provides for liposomes having combined therapeutic and diagnostic utilities by co-encapsulating ionically coupled diagnostic and therapeutic agents, in one embodiment, by a method using anionic chelators to prepare electrochemical gradients for loading of amphipathic therapeutic bases into liposomes already encapsulating an imaging agent. The invention provides for imaging of therapeutic liposomes by inserting a lipopolymer anchored, remotely sensing reporter molecules into liposomal lipid layer. The invention allows for an integrated delivery system capable of imaging molecular fingerprints in diseased tissues, treatment, and treatment monitoring.
Owner:SUTTER WEST BAY HOSPITALS
Reparative cell delivery via hyaluronic acid vehicles
Methods are described for generating autologous tissue grafts, including generating grafts at the point of case, which include isolated cell populations that are enriched with stem cells and are mixed with hyaluronic acid and derivatives thereof. The hyaluronic acid localizes the cells to a desired injection site and stimulates collagen production thus enhancing the viability and the longevity of the graft.
Owner:BOARD OF RGT THE UNIV OF TEXAS SYST +1
Device for magnetic immobilization of cells
InactiveUS7285412B2Strong yet uniform external magnetic fieldForce is smallBioreactor/fermenter combinationsBiological substance pretreatmentsMagnetic field gradientElectrical battery
The present invention relates to an apparatus and methods that immobilize one or more cells associated with magnetic material on a substrate on which are located one or more magnetic receptacle(s). Alternatively, in another aspect the present invention, the device arrays cells associated with magnetic material on a substrate having a pattern of magnetic receptacles disposed thereon. The size of the magnetic receptacle(s) determines the number of target cells that it is capable of immobilizing. The size of the magnetic receptacle is defined by the strength of a localized magnetic field gradient. The localized magnetic field gradient may be derived from 1) permanent magnets embedded in the substrate or alternatively, the localized magnetic field gradient may be derived from an 2) external magnet whose strength is focused by objects of highly-permeable-magnetic material which create localized magnetic field gradients. The invention apparatus comprises a removable cell delivery device and a substrate, which has one or more magnetic receptacles disposed thereon.
Owner:SURFACE LOGIX INC
Biocompatible substrate for facilitating interconnections between stem cells and target tissues and methods for implanting same
ActiveUS20120009159A1Minimize the risk of damageReduce traumaBiocideSenses disorderDiseaseInterconnection
Disclosed herein are substrates for cell delivery to target tissues requiring treatment for various diseases that induce cell death, damage or loss of function. The substrates are configured to provide seeded cells, including stem cells, with a structural support that allows interconnection with and transmission of biological signals between the cells and the target tissue.
Owner:RGT UNIV OF CALIFORNIA +3
Gene and Cell Delivery Self Expanding Polymer Stents
A device having polymeric filaments, wherein at least one of the filaments includes at least one groove for slidably retaining at least one other filament, such that the device is adapted to revert to a tubular lattice structure when allowed to expand from a collapsed state. A device as described above and further including a biologically active function, wherein the polymeric filaments of the device include an agent having a reactive group or a fiber adapted to covalently react with a biomaterial. Thus, the device of the invention has an active structural function such as the ability to regain a shape and, optionally, a biologically active function such as the ability to deliver a biomaterial to an organism or a cell. A process of manufacturing the device is also described.
Owner:THE CHILDRENS HOSPITAL OF PHILADELPHIA +1
Methods and compositions for enhancing the delivery of a nucleic acid to a cell
InactiveUS6919208B2Improve efficiencyEnhancing the cytoskeletal permissiveness of the cellOrganic active ingredientsMicroencapsulation basedCytoskeletonMammalian cell
Owner:THE CHILDRENS HOSPITAL OF PHILADELPHIA
Endosomolytic agents and cell delivery systems
The present invention provides improved cell delivery compositions. In particular, the invention provides biocompatible endosomolytic agents. In a preferred embodiment, the endosomolytic agents are also biodegradable and can be broken down within cells into components that the cells can either reuse of dispose of. In one aspect, the present invention provides endosomolytic agents capable of effecting the lysis of an endosome in response to a change in pH, and methods for effecting the lysis of an endosome. These inventive endosomolytic agents obviate the need for known agents (i.e., chloroquine, fusogenic peptides, inactivated adenoviruses and polyethyleneimine) that can burst endosomes and have negative effects on cells. In another aspect, the present invention provides cell delivery compositions comprising an endosomolytic component that is capable of effecting the lysis of the endosome in response to a change in pH, and an encapsulating, or packaging, component capable of packaging a therapeutic agent to be delivered to cellular or subcellular components.
Owner:MASSACHUSETTS INST OF TECH
Cell-specific gene delivery vehicles
InactiveUS20050074403A1Strengthen cellsImproved tissue-specific deliveryIn-vivo radioactive preparationsNanomedicineCell specificGene delivery
A delivery vehicle is described that is capable of being specifically bound to and taken into targeted cells, delivering numerous physiological agents, particularly paramagnetic ions for magnetic resonance imaging (MRI) of the cells. The delivery vehicle comprises a polymeric molecule having a net positive charge complexed with another polymeric molecule having a net negative charge. Cell targeting moieties and physiological agents, including contrast agents and therapeutic agents, are attached to one or both of the polymeric molecules. In one embodiment, the polymeric molecule having a net negative charge is a nucleic acid. Thus, the delivery vehicles can be used in clinical protocols in which nucleic acids for gene therapy and agents for MRI contrast are co-transported to specific cells allowing medical imaging monitoring of nucleic acid delivery.
Owner:CALIFORNIA INST OF TECH
Methods and apparatus for introducing cells at a tissue site
InactiveUS20130041265A1Reduce physical traumaEasy injectionCannulasSurgical needlesCellular viabilityTherapeutic intent
The present invention relates to methods and devices for maintaining cellular viability and function for therapeutic purposes. The invention provides methods and devices for maintaining the proliferative and developmental potential of cellular preparations by protecting the from physical and physiological damage during storage, preparation, and delivery to a site (e.g., a tissue site). The invention also provides methods and devices for evaluating tissues and organs, and selecting appropriate sites for cellular delivery.
Owner:BIOSTAGE INC
Cell targeting methods and compositions
In certain aspects, the invention relates to cell delivery compositions comprising a progenitor cell and a targeting moiety, and methods related thereto. Such compositions and methods may be used, for example, in administering a targeted cell therapy to a subject.
Owner:CAPLAN ARNOLDI
Magnetically-Controllable Delivery System for Therapeutic Agents
InactiveUS20100204674A1Enhanced magnetizationSaturation magnetizationStentsElectrotherapyMagnetic gradientMagnetization
Owner:DREXEL UNIV
Magnetic Nanoparticles and Uses Thereof
InactiveUS20130089614A1Increase profitGood flexibilityPowder deliveryMaterial nanotechnologyMagnetite NanoparticlesSilica gel
Magnetic nanoparticles are provided that have a superparamagnetic core and a nanoporous silica shell surrounding the core. The shell is functionalized with amine or S-nitrosothiol groups both inside and outside the nanopores. A process to provide such nanoparticles involves hydrolyzing tetraethoxysilane (TEOS) in a microemulsion of a superparamagnetic nanoparticle to form a superparamagnetic nanoparticle encapsulated by an incompletely hydrolyzed nanoporous silica shell, and hydrolyzing an amine-containing compound or a thiol-containing compound in situ in the presence of the incompletely hydrolyzed nanoporous silica shell before hydrolysis and densification of the silica shell is complete to functionalize the nanoporous silica shell with amine or thiol groups both inside and outside the nanopores and to maintain nanoporosity of the shell. Such magnetic nanoparticles are useful as carriers for chemical or biological species, particularly for magnetic resonance imaging, optical imaging, targeted drug delivery, cell delivery and magnetic separation applications.
Owner:ZHANG XUEFENG +1
Active scaffolds for on-demand drug and cell delivery
The invention provides a composition whose porosity, pore size, pore connectivity, swelling agent concentration, and / or specific volume undergoes a change from a first value to a second value in response to an electromagnetic signal, the composition having a matrix material in which is distributed a magnetic material.
Owner:PRESIDENT & FELLOWS OF HARVARD COLLEGE
Cell delivery matrices
Cell delivery matrices and methods for facilitating local delivery of adipose derived endothelial cells to a target tissue, body cavity, or joint are described. The cell delivery matrix may be a three-dimensional matrix scaffold comprising fibrin derived from the patient's own body. The cell delivery matrix may be biocompatible and semi-permeable. The cell delivery matrix used in the methods of the invention may be comprised of any degradable, bioabsorbable or non-degradable, biocompatible polymer. Regenerative therapies comprising implanting in the subject cell delivery matrices localizing adipose derived endothelial cells are described. The cell delivery matrices maintain the adipose derived endothelial cells at the target for a therapeutically effective amount of time. The adipose derived endothelial cells can be allogenic or syngenic to the subject. The endothelial cells may be delivered alone or in combination with other therapeutic agents.
Owner:TISSUE GENESIS LLC
Cell delivery patch for myocardial tissue engineering
A patch for cardiac tissue engineering includes a gel layer supported by an intermediate layer, which is attached to a reinforcement layer. These patches may be implanted in a heart to treat pediatric congenital malformations of the heart as well as adult ischemic myopathies. The gel layer may include cells such as, for example, stem cells; the intermediate layer may be biodegradable porous mesh and the reinforcement layer may be polytetrafluoroethylene. Included are methods for making patches according to the invention and for tissue engineering using patches of the invention.
Owner:THE TRUSTEES OF THE UNIV OF PENNSYLVANIA
Using of scaffold comprising fibrin for delivery of stem cells
The invention generally relates to the field of delivery of cells to desired tissue sites, prolonged retention of the cells at the sites, and integration of cells into an area of interest for increased therapeutic effect. The invention provides, in part, compositions and methods for treating ischemia in a subject in need thereof. In some aspects, the methods of treatment comprise the administration of a fibrin scaffold or fibrin clot comprising stem cells.
Owner:BAXTER INT INC +1
Use of cd34+ hematopoietic progenitor cells for the treatment of cns disorders
InactiveUS20050163760A1Improve bioavailabilityLengthening possible duration of treatmentBiocideNervous disorderDiseaseDuration treatment
The present invention provides novel methods for delivering cells, particularly modified cells to the central nervous system (CNS). The purpose of this invention is to present a method that provides sustained delivery of a molecule to the central nervous system, thereby increasing the bioavailability of the molecule and lengthening the possible duration of treatment.
Owner:INST NAT DE LA SANTE & DE LA RECHERCHE MEDICALE (INSERM)
Hydrogel membrane composition and use thereof
InactiveUS20040096505A1Change propertiesChange structureBiocidePowder deliveryMeth-Organic chemistry
The invention disclosed is a hydrogel composition for use as dural substitute, for wound closure of cleft palate and regeneration, and as substrate for cell delivery to the eye. The hydrogel is made of a copolymer of (a) an N-substituted (meth)acrylamide, and (b) a hydroxyalkyl (meth)acrylate, which is covalently crosslinked with dimethacrylate monomers. The swollen, gel is in the form of a sheet or membrane that is readily sterilisable, being homogeneous or heterogeneous, non-degradable, non resorbable, elastically deformable, and has an equilibrium water content of at least 50%.
Owner:WOERLY STEPHANE
Method for Preparing Porous Scaffold for Tissue Engineering, Cell Culture and Cell Delivery
ActiveUS20100221303A1Increase awarenessProvide protectionPowder deliveryBiocideCross-linkSufficient time
The present invention relates to a method for preparing a porous scaffold for tissue engineering. It is another object of the present invention to provide a porous scaffold obtainable by the method as above described, and its use for tissue engineering, cell culture and cell delivery. The method of the invention comprises the steps consisting of: a) preparing an alkaline aqueous solution comprising an amount of at least one polysaccharide, an amount of a cross-linking agent and an amount of a porogen agent b) transforming the solution into a hydrogel by placing said solution at a temperature from about 4° C. to about 80° C. for a sufficient time to allow the cross-linking of said amount of polysaccharide and c) submerging said hydrogel into an aqueous solution d) washing the porous scaffold obtained at step c).
Owner:UNIVERSITÉ PARIS CITÉ
Receptors
InactiveUS20060135418A1Structure miniaturizationImprove bindingImmunoglobulin superfamilyIn-vivo radioactive preparationsDisulfide bondingAutoimmune condition
A multivalent T cell receptor (TCR) complex comprising at least two TCRs, linked by a non-peptidic polymer chain or a peptidic linker sequence. Preferably the TCR complex comprises TCR heterodimers having a non-native disulfide bond between constant domain residues, said TCRs being linked via an optionally substituted, polyalkylene glycol linker. Therapeutic agents such as cytotoxic drugs may be attached to such complexes for targeted cell delivery. Such TCR complexes may be used in the diagnosis or treatment of cancer, infectious disease, or autoimmune disease.
Owner:IMMUNOCORE LTD
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com